[go: up one dir, main page]

BR0213380A - Derivados propiÈnicos alfa-oxissubstituìdos por beta-fenila: processo para sua preparação e seu uso na preparação de compostos farmaceuticamente importantes - Google Patents

Derivados propiÈnicos alfa-oxissubstituìdos por beta-fenila: processo para sua preparação e seu uso na preparação de compostos farmaceuticamente importantes

Info

Publication number
BR0213380A
BR0213380A BR0213380-6A BR0213380A BR0213380A BR 0213380 A BR0213380 A BR 0213380A BR 0213380 A BR0213380 A BR 0213380A BR 0213380 A BR0213380 A BR 0213380A
Authority
BR
Brazil
Prior art keywords
preparation
oxisubstituted
beta
alpha
important compounds
Prior art date
Application number
BR0213380-6A
Other languages
English (en)
Inventor
Debnath Bhuniya
Saibal Kumar Das
Gurram Ranga Madhavan
Javed Iqbal
Ranjan Chakrabarti
Mohan Chander
Sankar Mohan
Original Assignee
Reddys Lab Ltd Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr
Publication of BR0213380A publication Critical patent/BR0213380A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"DERIVADOS PROPIÈNICOS ALFA-OXISSUBSTITUìDOS POR BETA-FENILA: PROCESSO PARA SUA PREPARAçãO E SEU USO NA PREPARAçãO DE COMPOSTOS FARMACEUTICAMENTE IMPORTANTES". A presente invenção refere-se a novos derivados de ácido propiónico. Mais particularmente, a presente invenção refere-se a ácidos propiónicos alfa-oxissubstituídos por beta-fenila da fórmula geral (I). A presente invenção também refere-se a processos para a preparação de compostos da fórmula (I) e seu uso na preparação de compostos de fórmula (II).
BR0213380-6A 2001-10-16 2002-10-15 Derivados propiÈnicos alfa-oxissubstituìdos por beta-fenila: processo para sua preparação e seu uso na preparação de compostos farmaceuticamente importantes BR0213380A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN848CH2001 2001-10-16
PCT/IB2002/004274 WO2003033456A1 (en) 2001-10-16 2002-10-15 NOVEL β-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS

Publications (1)

Publication Number Publication Date
BR0213380A true BR0213380A (pt) 2005-02-01

Family

ID=11097010

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0213380-6A BR0213380A (pt) 2001-10-16 2002-10-15 Derivados propiÈnicos alfa-oxissubstituìdos por beta-fenila: processo para sua preparação e seu uso na preparação de compostos farmaceuticamente importantes
BR0213350-4A BR0213350A (pt) 2001-10-16 2002-10-15 Derivados benzoxazina e benzotiazina e composições farmacêuticas contendo os mesmos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0213350-4A BR0213350A (pt) 2001-10-16 2002-10-15 Derivados benzoxazina e benzotiazina e composições farmacêuticas contendo os mesmos

Country Status (14)

Country Link
US (2) US20110105748A1 (pt)
EP (2) EP1436247A1 (pt)
JP (2) JP2005505617A (pt)
CN (2) CN1589258A (pt)
BR (2) BR0213380A (pt)
CA (2) CA2463685A1 (pt)
HR (2) HRP20040350A2 (pt)
HU (2) HUP0401647A3 (pt)
IL (2) IL161429A0 (pt)
NO (2) NO20041998L (pt)
NZ (1) NZ532285A (pt)
PL (2) PL369732A1 (pt)
WO (2) WO2003033481A1 (pt)
ZA (2) ZA200402858B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040102A2 (en) * 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd. Novel compounds and their use as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
ITRM20050389A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
JP2009536954A (ja) 2006-05-11 2009-10-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｅｔｐ阻害剤としての３，４−ジヒドロ−２ｈ−ベンゾ［１，４］オキサジンおよびチアジン誘導体
JP2009536953A (ja) 2006-05-11 2009-10-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｅｔｐ阻害剤としての１，２，３，４−テトラヒドロ−キノリン誘導体
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
CN110403942A (zh) * 2007-04-11 2019-11-05 奥默罗斯公司 预防和治疗成瘾的组合物和方法
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
US8754127B2 (en) 2009-02-16 2014-06-17 Nogra Pharma Limited Alkylamido compounds and uses thereof
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
AU2011254726B2 (en) 2010-05-19 2014-03-06 Upfield Europe B.V. Theobromine for increasing HDL-cholesterol
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
BR112013021236B1 (pt) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
CN104254327A (zh) 2012-02-09 2014-12-31 诺格拉制药有限公司 治疗纤维化的方法
BR112014026160A2 (pt) 2012-04-18 2017-07-18 Nogra Pharma Ltd métodos para tratar intolerância à lactose
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2015010935A (es) 2013-02-22 2015-10-29 Merck Sharp & Dohme Compuestos biciclicos antidiabeticos.
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2992057B1 (en) * 2013-04-30 2018-01-31 3M Innovative Properties Company Process for preparing poly(benzoxazines)
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
AU2015287663B2 (en) * 2014-07-10 2019-02-28 SpecGx LLC Process for preparing substituted phenylalkanes
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
UA129325C2 (uk) 2019-02-08 2025-03-19 Ногра Фарма Лімітед Спосіб одержання 3-(4'-амінофеніл)-2-метоксипропіонової кислоти, її аналогів і проміжних сполук
CN113968781A (zh) * 2021-11-11 2022-01-25 上海吉奉生物科技有限公司 一种(s)-2-羟基-3-邻甲基丙酸的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0816316A4 (en) * 1995-03-10 1999-06-02 Nitto Chemical Industry Co Ltd Process for producing 1,2-ethanediol derivatives
CN100357281C (zh) * 1998-05-27 2007-12-26 雷迪实验室有限公司 双环化合物、其制备方法和包含它们的药物组合物
CZ20013832A3 (cs) 1999-04-28 2002-04-17 Dr. Reddy's Research Foundation Substituované bicyklické heterocyklické sloučeniny, způsob jejich přípravy a jejich pouľití jako antiobezitních a hypocholesterolemických činidel
SE9904421D0 (sv) * 1999-12-03 1999-12-03 Astra Ab New compounds
AU2002212672A1 (en) 2000-10-12 2002-04-22 Dr. Reddy's Research Foundation Salts of benzothiazine and benzoxazine derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
BR0213350A (pt) 2004-10-13
CN1596249A (zh) 2005-03-16
EP1436247A1 (en) 2004-07-14
EP1436268A1 (en) 2004-07-14
HUP0401649A2 (hu) 2004-11-29
US20110105748A1 (en) 2011-05-05
CA2463685A1 (en) 2003-04-24
HRP20040349A2 (en) 2005-06-30
HUP0401647A2 (hu) 2004-11-29
JP2005505617A (ja) 2005-02-24
WO2003033481A1 (en) 2003-04-24
US20050113368A1 (en) 2005-05-26
NO20041998D0 (no) 2004-05-14
CA2463686A1 (en) 2003-04-24
NO20041998L (no) 2004-07-02
US7365064B2 (en) 2008-04-29
PL369655A1 (en) 2005-05-02
CN1589258A (zh) 2005-03-02
NZ532285A (en) 2005-11-25
IL161431A0 (en) 2004-09-27
JP2005527480A (ja) 2005-09-15
PL369732A1 (en) 2005-05-02
IL161429A0 (en) 2004-09-27
HUP0401647A3 (en) 2008-05-28
NO20041994L (no) 2004-05-14
HUP0401649A3 (en) 2007-05-29
ZA200402910B (en) 2005-01-13
WO2003033456A1 (en) 2003-04-24
ZA200402858B (en) 2005-01-12
HRP20040350A2 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
BR0213380A (pt) Derivados propiÈnicos alfa-oxissubstituìdos por beta-fenila: processo para sua preparação e seu uso na preparação de compostos farmaceuticamente importantes
DOP2002000512A (es) Sales de acido succinato de 5,7,14-triazatetraciclo [10.3.1.0² ¹¹.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas
BR0214469A (pt) 17alfa-alquil-17beta-óxi-estratrienos e produtos intermediários para sua preparação, aplicação dos 17alfa-alquil-17beta-óxi-estratrienos para a preparação de medicamentos bem como preparações farmacêuticas
BR0112693A (pt) (derivados) de ácido sulfonilaminometilbenzóico substituìdos e processo para preparação do mesmo
BR0009411A (pt) Composto de anilina substituìda, e, processo para a preparação e uso de compostos
BR0116723A (pt) Derivados de tioéster de ácido tiazolil acético e seu uso na preparação de compostos de cefalosporina
DK0422485T3 (da) Quinoloncarboxylsyrederivater, fremgangsmåder til deres fremstilling samt deres anvendelse som antivirale midler
BR0015147A (pt) Ciclopropanos como cgrp-antagonistas, medicamentos contendo os ditos compostos e processo para a produção dos mesmos
BR0110430A (pt) Processo para a preparação de um composto, composto, e, uso do mesmo
ES2105362T3 (es) Nuevos derivados de acidos quinolon- y naftiridoncarboxilicos.
BR0213481A (pt) Sondas
BR0208999A (pt) Processo para a preparação de ácido de cefpodoxima
BR0007982A (pt) Processo para a preparação de um composto, e,composto
PT1165485E (pt) Processo para a preparacao de produtos intermediarios pesticidas
BR0013799A (pt) Processo para a preparação de um composto, e, composto
BRPI0012329B8 (pt) derivados de benzofurano, processo para sua preparação e uso dos mesmos.
BRPI0407377A (pt) Processo para a preparação de aminoácidos bicìclicos aromáticos e intermediários dos mesmos
BR0000184A (pt) Processo para a preparação de compostos heterocìclicos
PT1280812E (pt) Ciclipostinas, processo para a sua preparacao e sua utilizacao
BR0209844A (pt) Processo para a separação de imipenem cristalino
BR9406352A (pt) Processo para a fabricição de ácido aminometanofosfonico
BR0114060A (pt) Processo para a preparação de delta1-pirrolinas
BR0009277A (pt) Processo de preparação de ácido propiÈnico de 3s-3-amino-3-arila e derivados deste
BR9713587A (pt) Derivados de ácido 4-(1-piperazinil) benzóico, processo para preparação dos mesmos e suas aplicações terapêuticas
BRPI0413530A (pt) compostos de cicloalquilamidoácido, processo para preparação e seus usos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]